source
- Replimune secures FDA accelerated approval for melanoma therapy after two prior rejectionsReplimune, a biotech based in Massachusetts, has received accelerated approval from the U.S. Food and Drug Administration for its melanoma drug. The approval comes after the therapy was rejected tw…
- Tarsus Pharma to spend $450M upfront acquiring Alkeus to expand its ophthalmology pipelineTarsus Pharmaceuticals announced it will acquire Alkeus Pharmaceuticals, a Phase 3 biotech focused on a Stargardt disease drug, for an upfront payment of $450 million. The deal is intended to broad…